Cargando…
Mutation profile in Indian primary myelofibrosis patients and its clinical implications
BACKGROUND: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by abnormal proliferation of megakaryocytes, bone marrow fibrosis, and extramedullary hematopoiesis. We did mutation profile of 50 patients of PMF and tried to correlate it with initial clinical presentation...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699232/ https://www.ncbi.nlm.nih.gov/pubmed/31489296 http://dx.doi.org/10.4103/sajc.sajc_276_18 |
_version_ | 1783444679340064768 |
---|---|
author | Patil, Vinod R. Chandrakala, S. Mantri, Shruti Patil, Rajesh Wasekar, Nilesh Jijina, Farah |
author_facet | Patil, Vinod R. Chandrakala, S. Mantri, Shruti Patil, Rajesh Wasekar, Nilesh Jijina, Farah |
author_sort | Patil, Vinod R. |
collection | PubMed |
description | BACKGROUND: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by abnormal proliferation of megakaryocytes, bone marrow fibrosis, and extramedullary hematopoiesis. We did mutation profile of 50 patients of PMF and tried to correlate it with initial clinical presentation of these patients. MATERIALS AND METHODS: All new and follow up patients who were diagnosed as PMF based on WHO 2016 definition of PMF were included. Mutation profile of these patients including JAK2 V617F, JAK2 exon 12, CALR and MPL mutations was done and all clinical, demographic and laboratory details were recorded. RESULTS: Total 50 patients were enrolled out of which 29 were males and 21 were females. Out of these patients, 32 (64%) were JAK2 positive, 13 (26%) were CALR positive, 1 (2%) were MPL positive and 4 (8%) were triple negative. As compared to JAK2+ve patients and triple negative group, CALR positive patients were younger, had lower total leucocyte count, larger spleen size, lower dynamic international prognostic scoring system (DIPSS) score and higher grade of fibrosis of marrow. CONCLUSION: This study depicts that incidence of JAK2 and CALR mutations in Indian PMF patients is fairly similar to that in rest of the world. CALR positive patients have better clinical parameters at presentation and have better prognosis as compared to JAK2 positive patients. |
format | Online Article Text |
id | pubmed-6699232 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-66992322019-09-05 Mutation profile in Indian primary myelofibrosis patients and its clinical implications Patil, Vinod R. Chandrakala, S. Mantri, Shruti Patil, Rajesh Wasekar, Nilesh Jijina, Farah South Asian J Cancer ORIGINAL ARTICLE: Hematolymphoid Malignancies BACKGROUND: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by abnormal proliferation of megakaryocytes, bone marrow fibrosis, and extramedullary hematopoiesis. We did mutation profile of 50 patients of PMF and tried to correlate it with initial clinical presentation of these patients. MATERIALS AND METHODS: All new and follow up patients who were diagnosed as PMF based on WHO 2016 definition of PMF were included. Mutation profile of these patients including JAK2 V617F, JAK2 exon 12, CALR and MPL mutations was done and all clinical, demographic and laboratory details were recorded. RESULTS: Total 50 patients were enrolled out of which 29 were males and 21 were females. Out of these patients, 32 (64%) were JAK2 positive, 13 (26%) were CALR positive, 1 (2%) were MPL positive and 4 (8%) were triple negative. As compared to JAK2+ve patients and triple negative group, CALR positive patients were younger, had lower total leucocyte count, larger spleen size, lower dynamic international prognostic scoring system (DIPSS) score and higher grade of fibrosis of marrow. CONCLUSION: This study depicts that incidence of JAK2 and CALR mutations in Indian PMF patients is fairly similar to that in rest of the world. CALR positive patients have better clinical parameters at presentation and have better prognosis as compared to JAK2 positive patients. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6699232/ /pubmed/31489296 http://dx.doi.org/10.4103/sajc.sajc_276_18 Text en Copyright: © 2019 The South Asian Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | ORIGINAL ARTICLE: Hematolymphoid Malignancies Patil, Vinod R. Chandrakala, S. Mantri, Shruti Patil, Rajesh Wasekar, Nilesh Jijina, Farah Mutation profile in Indian primary myelofibrosis patients and its clinical implications |
title | Mutation profile in Indian primary myelofibrosis patients and its clinical implications |
title_full | Mutation profile in Indian primary myelofibrosis patients and its clinical implications |
title_fullStr | Mutation profile in Indian primary myelofibrosis patients and its clinical implications |
title_full_unstemmed | Mutation profile in Indian primary myelofibrosis patients and its clinical implications |
title_short | Mutation profile in Indian primary myelofibrosis patients and its clinical implications |
title_sort | mutation profile in indian primary myelofibrosis patients and its clinical implications |
topic | ORIGINAL ARTICLE: Hematolymphoid Malignancies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699232/ https://www.ncbi.nlm.nih.gov/pubmed/31489296 http://dx.doi.org/10.4103/sajc.sajc_276_18 |
work_keys_str_mv | AT patilvinodr mutationprofileinindianprimarymyelofibrosispatientsanditsclinicalimplications AT chandrakalas mutationprofileinindianprimarymyelofibrosispatientsanditsclinicalimplications AT mantrishruti mutationprofileinindianprimarymyelofibrosispatientsanditsclinicalimplications AT patilrajesh mutationprofileinindianprimarymyelofibrosispatientsanditsclinicalimplications AT wasekarnilesh mutationprofileinindianprimarymyelofibrosispatientsanditsclinicalimplications AT jijinafarah mutationprofileinindianprimarymyelofibrosispatientsanditsclinicalimplications |